000130924 001__ 130924
000130924 005__ 20240228145558.0
000130924 0247_ $$2doi$$a10.1249/MSS.0000000000001357
000130924 0247_ $$2pmid$$apmid:28657933
000130924 0247_ $$2ISSN$$a0025-7990
000130924 0247_ $$2ISSN$$a0195-9131
000130924 0247_ $$2ISSN$$a1530-0315
000130924 0247_ $$2altmetric$$aaltmetric:21408442
000130924 037__ $$aDKFZ-2017-06000
000130924 041__ $$aeng
000130924 082__ $$a610
000130924 1001_ $$0P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aWiskemann, Joachim$$b0$$eFirst author$$udkfz
000130924 245__ $$aImpact of HSCT Conditioning and Glucocorticoid Dose on Exercise Adherence and Response.
000130924 260__ $$aPhiladelphia, Pa.$$bLippincott Williams & Wilkins$$c2017
000130924 3367_ $$2DRIVER$$aarticle
000130924 3367_ $$2DataCite$$aOutput Types/Journal article
000130924 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1525776357_10339
000130924 3367_ $$2BibTeX$$aARTICLE
000130924 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130924 3367_ $$00$$2EndNote$$aJournal Article
000130924 520__ $$aEvidence from randomized controlled trials (RCT) that exercise interventions have beneficial effects in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) is growing. However, intensive chemotherapy conditioning and glucocorticoid (GC) treatment is always part of an allo-HSCT and possibly affect exercise adherence and training response. Therefore, we aimed to examine whether various conditioning protocols or different doses of GC treatment affect exercise adherence and/or training response during the inpatient period.We analyzed inpatient data from intervention groups of two large RCT in allo-HSCT patients (n = 113). The intervention incorporated partly supervised endurance and resistance exercise three to five times per week. According to the potentially interfering factors, the patients were divided into groups depending on intensity of conditioning (myeloablative conditioning (MAC), reduced-intensity conditioning (RIC), and nonmyeloablative conditioning (NMC)) and cumulative dose of GC treatment (GC low ≤9 mg·kg prednisone or GC high >9 mg·kg prednisone) and were compared.Median exercise adherence (target value, five sessions weekly) during the inpatient period was 64% in MAC, 54% in RIC, and 63% in NMC. The proportion of prematurely terminated training sessions ranged from 11% to 15%. Tiredness was the most frequent cause of exercise termination in all groups. Exercise adherence, duration (min·wk) and type of training was significantly associated with GC dose. With regard to training response, results suggest that GC-low patients tend to respond better in knee extensor muscle strength.Exercise adherence during inpatient period is significantly affected by dose of GC treatment but not by condition regimen. However, given the reasonable adherence rates also in the GC-high group, data support the feasibility and importance of exercising for all allo-HSCT patients during the inpatient period.
000130924 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000130924 588__ $$aDataset connected to CrossRef, PubMed,
000130924 7001_ $$aHerzog, Benedikt$$b1
000130924 7001_ $$0P:(DE-HGF)0$$aKuehl, Rea$$b2
000130924 7001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b3$$udkfz
000130924 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b4$$udkfz
000130924 7001_ $$aSchwerdtfeger, Rainer$$b5
000130924 7001_ $$aDreger, Peter$$b6
000130924 7001_ $$aBohus, Martin$$b7
000130924 773__ $$0PERI:(DE-600)2031167-9$$a10.1249/MSS.0000000000001357$$gVol. 49, no. 11, p. 2143 - 2150$$n11$$p2143 - 2150$$tMedicine and science in sports and exercise$$v49$$x0195-9131$$y2017
000130924 909CO $$ooai:inrepo02.dkfz.de:130924$$pVDB
000130924 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000130924 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000130924 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000130924 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000130924 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000130924 9141_ $$y2017
000130924 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000130924 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000130924 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130924 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130924 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130924 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMED SCI SPORT EXER : 2015
000130924 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000130924 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000130924 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130924 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130924 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130924 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130924 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000130924 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130924 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000130924 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x0
000130924 980__ $$ajournal
000130924 980__ $$aVDB
000130924 980__ $$aI:(DE-He78)G210-20160331
000130924 980__ $$aUNRESTRICTED